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Corticosteroid therapy for sepsis: a clinical 
practice guideline
Francois Lamontagne,1  2 Bram Rochwerg,3  4 Lyubov Lytvyn,4 Gordon H Guyatt,4  
Morten Hylander Møller,5 Djillali Annane,6 Michelle E Kho,7 Neill K J Adhikari,8  9  
Flavia Machado,10  11 Per O Vandvik,12  13 Peter Dodek,14 Rebecca Leboeuf,15 Matthias Briel,4  16 
Madiha Hashmi,17 Julie Camsooksai,18 Manu Shankar-Hari,19  20 Mahder Kinfe Baraki,21  
Karie Fugate,22 Shunjie Chua,23 Christophe Marti,24 Dian Cohen,25 Edouard Botton,26  
Thomas Agoritsas,4  27 Reed A C Siemieniuk4
Do corticosteroids reduce death or improve 
recovery in people with sepsis or septic shock? 
Our panel make a weak recommendation to 
give corticosteroids to people with all types 
and severity of sepsis, based on new evidence. 
Because we are not certain that they are 
beneficial, it is also reasonable not to prescribe 
them. Patients’ values and preferences may guide 
this decision-making process.
This rapid recommendation was triggered by two 
trials, with differing conclusions whose results might 
change practice:
•   ADRENAL (3658 patients who had septic shock) 
found no statistically significant difference in 90 
day mortality between the hydrocortisone and 
placebo groups.1
•   APROCCHSS (1241 patients who had septic 
shock) found that hydrocortisone plus 
fludrocortisone reduced 90 day mortality.2
The trials are incorporated into a linked system-
atic review comparing corticosteroids with pla-
cebo.3 This BMJ Rapid Recommendation promptly 
and transparently translates this evidence using 
GRADE methodology for trustworthy guidelines. 
Sepsis is a life threatening organ dysfunction from 
infection. C urrently most guidelines advise against 
giving corticosteroids in sepsis in the absence of 
refractory shock, but these guidelines have not taken 
into account the new evidence. We do not anticipate 
that new clinical trials will substantively alter the 
evidence suggesting a small but uncertain mortality 
reduction. The box below shows publications linked 
in this Rapid Recommendation package. The main 
infographic provides an overview of the absolute 
benefits and harms. The table at the end of the arti-
cle shows any evidence that has emerged since the 
publication of this guideline.
Current understanding
Sepsis is life threatening organ dysfunction caused by a 
dysregulated host response to infection.4 In practice, a 
sepsis-related organ failure assessment (SOFA) score of 
≥2 in patients with infections is sepsis (table 1).4 5 World-
wide, about 30 million people are hospitalised with sep-
sis every year and up to six million of them die.6
Clinicians typically manage sepsis with early, broad 
spectrum antibiotics. They may provide supportive 
treatment such as vasoactive drugs and mechanical ven-
tilation. They track and adjust treatment based on clini-
cal signs and laboratory data.7 Septic shock is the most 
severe form of sepsis. These patients experience profound 
circulatory, metabolic, and cellular abnormalities.4 8 They 
require vasopressors to maintain perfusion pressure and 
have elevated serum lactate concentrations despite ade-
quate fluid repletion.
WHAT YOU NEED TO KNOW
•   Sepsis is a syndrome of life threatening 
infection with organ dysfunction, and most 
guidelines do not advise use of corticosteroids 
to treat it in the absence of refractory shock
•   Two new trials of corticosteroid treatment for 
sepsis came to differing conclusions
•   Corticosteroids may reduce the risk of 
death by a small amount and increase 
neuromuscular weakness by a small amount, 
but the evidence is not definitive 
•   This guideline makes a weak recommendation 
for corticosteroids in patients with sepsis; 
both steroids and no steroids are reasonable 
management options
•   Fully informed patients who value avoiding 
death over quality of life and function would 
likely choose corticosteroids
Full author details can be found at 
the end of the article
Correspondence to:  
R A C Siemieniuk  
reed.siemieniuk@medportal.ca
Cite this as: BMJ 2018;362:k3284
doi: 10.1136/bmj.k3284
This BMJ Rapid Recommendation 
article is one of a series that 
provides clinicians with trustworthy 
recommendations for potentially 
practice changing evidence. 
BMJ Rapid Recommendations 
represent a collaborative effort 
between the MAGIC group (http://
magicproject.org/) and The 
BMJ. A summary is offered here 
and the full version including 
decision aids is on the MAGICapp 
(https://app.magicapp.org), for all 
devices in multilayered formats. 
Those reading and using these 
recommendations should consider 
individual patient circumstances, 
and their values and preferences 
and may want to use consultation 
decision aids in MAGICapp to 
facilitate shared decision making 
with patients. We encourage 
adaptation and contextualisation 
of our recommendations to local or 
other contexts. Those considering 
use or adaptation of content may 
go to MAGICapp to link or extract 
its content or contact The BMJ for 
permission to reuse content in this 
article.
Linked articles in the BMJ Rapid Recommendation cluster
• Lamontagne F, Rochwerg B, Lytvyn L, et al. Corticosteroid 
therapy for sepsis: a clinical practice guideline. BMJ 
2018;362:k3284
 – Summary of the results from the Rapid 
Recommendation process
• Rochwerg B, Oczkowski SJ, Siemieniuk RAC, et al. 
Corticosteroids in sepsis: an updated systematic review 
and meta-analysis. Crit Care Med 2018. doi:10.1097/
CCM.00000000000032623
 – Review and meta-analysis of all available randomised 
trials that assessed corticosteroid therapy for sepsis
• MAGICapp (https://app.magicapp.org/public/guideline/
EZ1w8n)
 – Expanded version of the results with multilayered 
recommendations, evidence summaries, and decision 
aids for use on all devices
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Population
Comparison
or
Corticosteroid 
therapy
No 
corticosteroid 
therapy
Usual care only
Intravenous 
corticosteroids 
plus usual care
Corticosteroids No corticosteroids 
Comparison of benefits and harms
Favours corticosteroids Favours no corticosteroids 
StrongStrong WeakWeak
We suggest corticosteroid therapy rather than no corticosteroid therapy. 
Either option is reasonable.
No important difference
Usual
care
Usual
care+
Recommendation applies to:
Recommendation does not apply to:
18 fewerMortality Low254236
Evidence qualityEvents per 1000 people
Mean number of days
Neuromuscular weakness Low303
Quality of Life None
Adults and children
Patients with pre-existing adrenal insufficiency
Non-infectious causes of shock
Neonates Pregnant women
Any infectious source
Patients with and without shock
53 fewer 250
Stroke Very low510
Myocardial infarction Very Low3027
Unknown
No important difference
No important difference
Length of ICU stay Moderate13.1
Intra abdominal
infections
Pneumonia
Anaphylactic
Cardiogenic
Hypovolaemic
CCS
0.7 fewer12.4
Length of hospital stay Moderate32.00.7 fewer31.3
People
 with sepsis
  SOFA score 
  of at least 2
Disclaimer: This infographic is not a clinical decision aid. This information is provided without any representations, conditions or warranties that it is accurate or up to date. BMJ and its licensors assume no responsibility 
for any aspect of treatment administered with the aid of this information. Any reliance placed on this information is strictly at the user's own risk. For the full disclaimer wording see BMJ's terms and conditions: 
http://www.bmj.com/company/legal-information/
Those who place more value on 
avoiding functional deterioration 
and maximising quality of life than 
on avoiding death may be more 
likely to choose not to use 
corticosteroids
Preferences and values
Patients at greatest risk of death 
(e.gs. those with shock, high 
qSOFA/SOFA scores) will probably 
have the greatest reduction in risk 
of death with corticosteroids
Risk of death
There are no clear differences in 
efficacy or adverse effects between 
different corticosteroids or 
corticosteroid combinations. Most 
studies used hydrocortisone
Choice of corticosteroid
Key practical issues
No key practical issuesInfusion or intermittent bolus dosing
Monitoring for serum sodium, potassium, and glucose
Corticosteroids No corticosteroids 
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It is possible that corticosteroids help improve the dys-
regulated immune response caused by sepsis9 and increase 
blood pressure if it is low.10 Some clinicians have found this 
biological rationale, and results of early studies, compel-
ling. Others disagree and do not use corticosteroids.11
Most professional organisations recommend against 
corticosteroid use in the absence of refractory shock.12 
Table 2 summarises current professional society guide-
lines.
The evidence
The linked systematic review identified 42 randomised 
controlled trials (RCTs) comparing corticosteroids with 
no corticosteroids (typically placebo).3 Figure 2 provides 
an overview of the trials and participants.
The systematic review includes total of 10 194 patients 
who had sepsis. Of the 42 trials included, 24 restricted 
enrolment to patients who had septic shock. The typical 
patient was critically ill—a median of 32% of participants 
died within the first month. The most common sources 
of sepsis were pulmonary infections (median 44%) and 
abdominal infections (median 17%). Most of the RCTs 
used hydrocortisone alone (n=26), others used hydrocor-
tisone plus fludrocortisone (n=2), methylprednisolone 
(n=6), prednisolone (n=3), or dexamethasone (n=3) 
(see fig 2). Although most of the clinical trials included 
patients who had septic shock, many included patients 
who did not (16 trials, 2241 patients). The linked system-
atic review provides detailed trial descriptions, including 
risk of bias assessments and patient characteristics.3
Subgroups of patients 
Corticosteroids did not seem to be more or less effective 
in particular clinical subgroups, for example:
•   Septic shock
•   Pneumonia
•   Acute respiratory distress syndrome (ARDS)
•   Higher baseline risk of death
•   Different corticosteroid drugs (such as 
hydrocortisone, methylprednisolone)
•   Different corticosteroid doses
•   Different corticosteroid regimens (such as single 
agents or corticosteroid combinations such as 
hydrocortisone plus fludrocortisone)
•   More recent v older trials
•   Trials with higher v lower risk of bias.
Older studies tended to use much higher doses of corti-
costeroids for a shorter time than are typically used now; 
the pooled evidence from these older studies is imprecise 
(few events), and the linked meta-analysis was under-
powered to detect important subgroup differences such 
as by dose. All tests for relative subgroup effects may 
be underpowered to detect true differences because the 
effect sizes are small, especially for mortality. Therefore, 
we cannot be certain that a true subgroup effect does not 
exist. Future meta-analyses of individual patient data 
may help to identify populations that benefit more or 
less from corticosteroids. Until such time, we can only 
conclude that the evidence applies to all subgroups.
Understanding the recommendation
The main infographic provides an overview including the 
benefits and harms, and our certainty in the evidence for 
each outcome.
Absolute benefits and harms
There was better survival in the group taking corticoster-
oids, but this was not certain. This drives the weak rather 
than strong recommendation.
Mortality 
Corticosteroids may reduce mortality in the first month 
after admission to an intensive care unit (ICU) by approxi-
mately 2%. However, the panel had low certainty that 
this is true. The confidence interval crosses the line of no 
difference, and the results were inconsistent, with some 
RCTs showing a mortality reduction and others showing 
none.
Table 1 | Sepsis-related organ failure assessment (SOFA) score to help diagnose sepsis (adapted 
from Vincent et al5)*
System or organ and 
measure
SOFA score
0 1 2 3 4
Respiratory: 
 PaO2/FiO2, mm Hg ≥400 300-399 200-299 100-199 with 
respiratory support
<100 with 
respiratory 
support
Coagulation:
 Platelets, × 103/μL ≥150 100-149 50-99 20-49 <20
Liver:
 Bilirubin, μmol/L (mg/dL) <20 (1.2) 20-32 (1.2-1.9) 33-101 (2.0-5.9) 102-204 (6.0-11.9) >204 (12.0)
Circulatory:
 Mean arterial pressure, 
mm Hg
≥70 <70 Low dose 
dopamine 
or any dose 
dobutamine
Low-medium dose 
noradrenalin or 
adrenalin; medium 
dose dopamine
High dose 
noradrenalin, 
adrenalin, or 
dopamine
Central nervous system:
 Glasgow Coma Scale 
score
15 13-14 10-12 6-9 <6
Renal: 
 Creatinine, μmol/L 
(mg/dL)
<110 
(1.2)
110-170 (1.2-
1.9)
171-299 (2.0-
3.4)
300-440 (3.5-4.9) >440 (5.0)
 Urine output, mL/day – – – <500 <200
*Our recommendation applies to patients with an infection and a SOFA score of ≥2. 
PaO2 = partial pressure of oxygen (arterial). FiO2 = fraction of inspired oxygen.
Table 2 | Current recommendations for corticosteroid therapy in patients with sepsis
Society
Recommendation regarding corticosteroid use 
In sepsis In septic shock Other situations
“Surviving Sepsis” 
for SCCM and 
ESICM, 20167
Against In favour for hypotension 
refractory to fluid resuscitation 
and vasopressor
History of adrenal insufficiency or 
corticosteroid use
CIRCI guidelines 
for SCCM and 
ESICM, 201812 13
Against In favour for shock not responsive 
to fluid and at least moderate 
dose vasopressor
Acute respiratory distress syndrome 
Community acquired pneumonia 
Bacterial meningitis 
History of adrenal insufficiency or 
corticosteroid use
CAEP, 200814 Against In favour for haemodynamically 
unstable patients not responsive 
to fluid resuscitation and 
vasopressor
NICE, 201715 Not mentioned Not mentioned Not mentioned
JSICM, 201816 Against In favour for shock not responsive 
to initial fluid resuscitation and 
vasoactive drugs
SCCM = Society of Critical Care Medicine. ESICM = European Society for Intensive Care Medicine. CIRCI = critical illness-related 
corticosteroid insufficiency. CAEP = Canadian Association of Emergency Physicians. NICE = National Institute for Health and 
Care Excellence (UK). JSICM = Japanese Society for Intensive Care Medicine.
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The effect on longer term mortality (from 60 days to 1 
year) was similar. Fewer studies reported this outcome, 
so, although the results were consistent in the RCTs that 
did report this outcome, the panel also had low certainty 
that corticosteroids reduce longer term mortality.
Quality of life 
No RCT reported quality of life outcomes at any time 
point. The ADRENAL study investigators are collecting 
quality of life data at six months, but these data have not 
been published.17
Outcomes of some interest 
Corticosteroids may reduce the length of ICU and hospital 
stay by less than a day each (moderate quality evidence). 
The impact of corticosteroids on other patient-important 
outcomes such as stroke and myocardial infarction was 
extremely uncertain. They may increase the risk of neuro-
muscular weakness by a small amount (low quality evidence 
from seven RCTs). Possible explanations include the toxic 
effects on nerve and muscle cells, and hyperglycaemia from 
corticosteroid use.18 Weakness may compromise patients’ 
ability to function independently19 and delay recovery.20
In two of the seven RCTs evaluating weakness, it was 
prospectively evaluated one month after enrolment.2 21 
Evaluations of neuromuscular weakness, especially in 
RCTs that relied on investigator identification, were unre-
liable. The panel therefore believed that the RCTs proba-
bly underestimated the risk of neuromuscular weakness.
Outcomes of less importance 
Corticosteroids probably increase the risk of hypergly-
caemia and hypernatraemia. Corticosteroids probably 
improve organ function at day 7 and the chance of shock 
reversal at day 7.
Patient subgroups 
Our recommendation applies to all patients with sepsis. 
There was no meaningful difference in the efficacy of 
corticosteroids in different groups of patients including 
those with septic shock, pneumonia, acute respiratory 
distress syndrome, or other sources of sepsis, or those 
who were sicker. However, the absolute reduction in 
mortality from corticosteroids will be greater in patients 
with a higher risk of death. The absolute harm (such as 
neuromuscular weakness) will also be greater in sicker 
patients.
The analysis of a subgroup effect showed no convincing 
evidence of such an effect. Based on published criteria for 
credible subgroup effects,22 in the absence of a subgroup 
Fig 2 |  Characteristics of patients and trials included in systematic review of the use of corticosteroids for treating sepsis3 
CAP = community acquired pneumonia. ARDS = acute respiratory distress syndrome.
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effect, the interpretation of the effect of corticosteroids in 
any particular subgroup should be guided by the effect in 
the overall population of septic patients.
Several trials of corticosteroids for pneumonia or acute 
respiratory distress syndrome have enrolled patients 
who did not have sepsis; we did not consider these tri-
als. Therefore, clinicians treating these conditions should 
also consider evidence23 24 and guidelines12 applicable 
to patients who have pneumonia and acute respiratory 
distress syndrome.
Patient values and preferences
Fully informed patients who place a higher value on 
avoiding death than on quality of life and function 
would be more likely to choose to receive corticosteroids. 
We heard from our patient partners that most patients 
will want to reduce their risk of death, even if this reduc-
tion is small and uncertain. This view is consistent with 
the experiences of the rest of the panel. Most patients 
will likely be willing to accept a small increased risk of 
weakness.
Patients (or their care givers and surrogate decision-
makers) will probably vary in how they would weigh 
the balance of expected desirable and undesirable con-
sequences from corticosteroids. We assume that most 
patients want to avoid death and will value even a small, 
uncertain reduction in mortality. We judge that they will 
be less concerned about the possible increase in weak-
ness among survivors. There is also likely to be a sizeable 
minority of patients who would place a large value on 
avoiding a very uncertain but possible decline in quality 
of life and functional abilities even at the cost of a small 
increase in risk of death.25 Shared decision making con-
versations about specific interventions in patients with 
sepsis may not always be feasible, and could delay care. 
However, clinicians should do their best to elicit each 
patient's values and preferences. For example, they could 
talk about the patient’s goals of care with the patient, 
their family, and friends.
Practical considerations
Figure 3 outlines the key practical issues for patients 
and clinicians discussing corticosteroid treatment for 
sepsis.
The optimal corticosteroid drug, dose, and duration 
of treatment are uncertain. Hydrocortisone was the 
most commonly used corticosteroid in the RCTs and is 
therefore a reasonable choice. Differences among cor-
ticosteroids, if they do exist, are probably small; dexa-
methasone, methylprednisolone, and prednisolone 
were also studied and produced similar results. Adding 
an agent that has additional mineralocorticoid activity, 
such as fludrocortisone, could be helpful, but that is 
highly speculative.
The typical hydrocortisone dose for an adult in the 
RCTs was 200-300 mg/day, given either as an infusion 
or as boluses every six hours.26 If an infusion is chosen, 
a bolus of 50-100 mg can be given before the infusion. 
In the RCTs the duration of treatment was typically 7-14 
days, or less for those who were rapidly improving.
Inflammation may recur after discontinuing corticos-
teroid therapy,27 especially when it is stopped abruptly.28 
Clinicians should carefully monitor all patients after dis-
continuing corticosteroids. In patients who deteriorate 
after stopping corticosteroids (such as development of 
shock or need for mechanical ventilation), reinitiating 
corticosteroid therapy could be helpful, although this 
is highly speculative. Whether corticosteroids should be 
tapered rather than stopped abruptly is unclear. Corticos-
teroid induced adrenal suppression is probably duration 
dependent, and so patients who receive longer courses of 
corticosteroids (such as >14 days) might be particularly 
likely to benefit from a taper before discontinuing and an 
evaluation of hypothalamo-pituitary-adrenal axis func-
tion if in doubt.12
HOW THIS RECOMMENDATION WAS CREATED
Our international panel included sepsis survivors, family 
caregivers of patients who had sepsis, intensivists, internists, 
nurses, an endocrinologist, physiotherapists, trialists, and 
methodologists (see appendix 1 on bmj.com). They decided 
on the scope of the recommendation and the outcomes that 
are most important to patients. The panel judged death and 
quality of life to be the most important outcomes. Myocardial 
infarction, stroke, duration of stay in hospital and in the 
intensive care unit (ICU), superinfections, and neuromuscular 
weakness (such as ICU-acquired weakness) were also 
identified as important outcomes for patients.
Surrogate outcomes such as time to shock reversal, 
organ dysfunction measured by the sepsis-related organ 
failure assessment (SOFA) score, hyperglycaemia, and 
hypernatraemia were less important to the panel. This view 
is consistent with GRADE recommendations to focus on 
patient-important outcomes rather than surrogates.29
Subgroups of interest—The panel wanted to know whether 
the effect of corticosteroids differed in people with sepsis, 
compared with people who had septic shock, pneumonia, 
acute respiratory distress syndrome, or were at higher risk 
of death.3 30 They also wanted to know whether the type of 
corticosteroid or its dose influenced outcomes.
The panel met by videoconference to discuss the evidence 
and formulate a recommendation. No panel member had 
financial conflicts of interest; intellectual and professional 
conflicts were minimised and managed (see appendix 2 on 
bmj.com).
The panel requested a systematic review of randomised 
controlled trials on the impact of corticosteroid therapy for 
patients who have sepsis, including those who have septic 
shock.3 This review examines the two latest, as well as 
previous studies, on corticosteroids in sepsis. The aim was 
to resolve apparently conflicting evidence.
The panel followed the BMJ Rapid Recommendations 
procedures for creating a trustworthy recommendation,31 
including using the GRADE approach to critically appraise 
the evidence and create recommendations (see appendix 
3 on bmj.com).32 The panel considered the balance of 
benefits, harms, and burdens of corticosteroids, the quality 
of the evidence for each outcome, expected variations 
in patient values and preferences, and acceptability 
of corticosteroids.33 Determining patient values and 
preferences occurred before the panel received the results of 
the meta-analysis to reduce the risk that opinions regarding 
outcome importance will be data driven. According to the 
GRADE approach, recommendations can be strong or weak 
and for or against a course of action.33 High quality evidence 
of an effect on surrogate outcomes do not trigger strong 
recommendations.
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Costs
Corticosteroids are typically inexpensive and widely 
available. The impact of corticosteroids on the overall 
costs to patients and to health systems is uncertain and 
would be driven mostly by ICU and hospital lengths of 
stay or prolonged periods of rehabilitation.
Future research
With the exception of the awaited analysis of quality of 
life in the ADRENAL trial, there are currently no planned 
or ongoing RCTs in patients who have sepsis that are likely 
to substantively change the overall effect estimates for the 
key outcomes. Given remaining u ncertainty regarding the 
Fig 3 |  Practical issues about use of corticosteroids for treatment of sepsis
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effect of corticosteroids in different subgroups, additional 
analyses of existing data to explore heterogeneity of treat-
ment effects are logical next steps before more patients 
are enrolled in similar trials. Such work mandates indi-
vidual patient-data meta-analyses that rely on investiga-
tors sharing the data from their RCTs and cooperation 
among research networks.
It is possible that additional adaptive RCTs could help 
to resolve remaining uncertainty. Key research questions 
to inform decision makers and future guidelines are:
•   What is the impact of corticosteroid therapy on 
quality of life in the short and long term?
•   What is the impact of corticosteroid therapy on 
functional recovery?
•   What is the impact of corticosteroid therapy on 
healthcare costs?
•   Are there subgroups of patients with sepsis who 
benefit more or less from corticosteroid therapy?
•   Are there differences between bolus and infusion 
dosing?
•   Does the addition of fludrocortisone improve outcomes?
Updates to this article
The final table shows evidence that has emerged since 
the publication of this article. As new evidence is pub-
lished, a group will assess the new evidence and make 
a judgment on to what extent it is expected to alter the 
recommendation.
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